Biodexa posted a loss attributable to shareholders of GBP 1.84 million in 1H 2026, narrowing from GBP 3.81 million a year earlier.
R&D costs rose 75% to GBP 2.92 million, driven by higher Serenta trial spending and MTX240 manufacturing costs.
Administrative costs fell 27% to GBP 1.74 million, primarily due to foreign exchange movements.
Net cash used in operating activities increased to GBP 4.61 million; cash totaled GBP 3.23 million at June 30, 2026.
Post-period, the company raised USD 3.5 million; Serenta enrolled 92 of 168 subjects, while CEO Stephen Stamp said MTX240 could show efficacy by end-2027.
BDRX•
